Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers.

Molecular cancer therapeutics - 1 Mar 2014

Nan Jing, Du Yuping, Chen Xing, Bai Qifeng, Wang Yuxin, Zhang Xinxin, Zhu Ning, Zhang Jing, Hou Jianwen, Wang Qin, Yang Jinbo

Abstract excerpt

Epidermal growth factor receptor (EGFR) is a clinical therapeutic target to treat a subset of non-small cell lung cancer (NSCLC) harboring EGFR mutants. However, some patients with a similar kind of EGFR mutation show intrinsic resistance to tyrosine kinase inhibitors (TKI). It indicates that oth...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Drug Synergism
Share to Gefitinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to I-kappa B Proteins

Share to NF-kappa B

Share to Quinazolines

Share to STAT3 Transcription Factor

Share to Thiophenes

Source

Identifiers

PMID: 24401319
DOI: 10.1158/1535-7163.MCT-13-0464

Genes

STAT3
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24401319-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers.PMID 24401319Read ↗

Repression of Smad3 by Stat3 and c-Ski/SnoN induces gefitinib resistance in lung adenocarcinoma.Semantic proximity Read ↗

The Fire Within: NF-κB Involvement in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.Semantic proximity Read ↗

Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literatureSemantic proximity Read ↗

The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable TargetSemantic proximity Read ↗

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.Semantic proximity Read ↗

Identification of C1qTNF-related protein 4 as a potential cytokine that stimulates the STAT3 and NF-κB pathways and promotes cell survival in human cancer cellsSemantic proximity Read ↗

A STAT inhibitor patent review: progress since 2011Semantic proximity Read ↗

Small Molecule Inhibitors of STAT3 for Cancer TherapySemantic proximity Read ↗

Signal transducer and activator of transcription 3 inhibitors: a patent reviewSemantic proximity Read ↗

Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib.Semantic proximity Read ↗

Targeting STAT3 by a small molecule suppresses pancreatic cancer progressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.